News

AbstractBackgroundLeft atrioventricular coupling index (LACI) has emerged as a powerful marker of cardiac remodeling across a variety of cardiac diseases, however…

Objective: To evaluate demographics, clinical presentation, diagnostic delay, treatment patterns, genotype-phenotype correlations, and outcomes in patients with…

- Acoramidis initiation was associated with rapid kidney-protective activity as exhibited in a hemodynamically mediated, reversible eGFR dip and a placebo-corrected…

Quiver AI SummaryBridgeBio Pharma, Inc. announced new data highlighting the kidney-protective benefits of acoramidis, a treatment for transthyretin amyloid…

In late February 2026, a research study by Dr Nguyen Van Te (Head of Nuclear Medicine at FV Hospital) and his colleagues was officially published in the Journal of…

AbstractAimsWhile cardiac magnetic resonance (CMR) provides prognostic value in transthyretin cardiac amyloidosis (ATTR-CA), current ATTR-CA staging relies on serum…

AbstractBackground Cardiac amyloidosis (CA) is frequently preceded by soft tissue infiltration, manifesting as orthopaedic "red flags" such as carpal tunnel…

Cardiovascular disease, the leading cause of deathTrusted Source globally, has not yet had an early-detection test — until now. On June 22, the Food and Drug…

AbstractInterpreting composite endpoints in cardiovascular drug development is a key challenge, particularly when events of different clinical relevance are…

Long-term treatment with diflunisal may help slow disease progression in people with hereditary transthyretin amyloidosis (hATTR), according to a Swedish real-world…